Advertisement

Topics

aap: Chairman of the Management Board / CEO Bruke Seyoum Alemu to retire early as of 30 April 2019; Rubino Di Girolamo appointed as successor as of 1 May 2019

10:25 EDT 15 Apr 2019 | EQS Group

aap Implantate AG / Key word(s): Personnel
aap: Chairman of the Management Board / CEO Bruke Seyoum Alemu to retire early as of 30 April 2019; Rubino Di Girolamo appointed as successor as of 1 May 2019

15-Apr-2019 / 14:25 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Supervisory Board of aap Implantate AG ("aap") and the Chairman of the Management Board / CEO, Bruke Seyoum Alemu (54), today agreed on an early termination of his term of office as of 30 April 2019. Bruke Seyoum Alemu thereupon resigned his mandate as Member and Chairman of the Management Board / CEO of aap by mutual agreement with the Supervisory Board with effect as of 30 April 2019 and will retire from the Management Board at this time. Mr. Alemu continues to be in charge of aap's operations as Chairman of the Management Board / CEO up to this time. Mr. Alemu will support the company on a consulting basis after his retirement from the Management Board.
 

Also with today's resolution, the Supervisory Board of the company appointed Mr. Rubino Di Girolamo (57), currently Member of the Supervisory Board at aap, as new Chairman of the Management Board / CEO of aap with effect as of 1 May 2019.


 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.


For inquiries please contact:

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de

15-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Original Article: aap: Chairman of the Management Board / CEO Bruke Seyoum Alemu to retire early as of 30 April 2019; Rubino Di Girolamo appointed as successor as of 1 May 2019

NEXT ARTICLE

More From BioPortfolio on "aap: Chairman of the Management Board / CEO Bruke Seyoum Alemu to retire early as of 30 April 2019; Rubino Di Girolamo appointed as successor as of 1 May 2019"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...